Related by context. All words. (Click for frequent words.) 77 platinum refractory 73 recurrent ovarian cancer 72 relapsed ovarian cancer 70 refractory ovarian cancer 70 heavily pretreated 70 metastatic renal cell carcinoma 69 HER2 positive metastatic breast 69 paclitaxel carboplatin 68 prostate cancer HRPC 68 refractory SCLC 67 refractory multiple myeloma 67 superficial bladder cancer 67 taxane chemotherapy 67 relapsed multiple myeloma 67 metastatic HRPC 67 docetaxel chemotherapy 67 alvespimycin 67 HRPC 66 bevacizumab Avastin ® 66 fallopian tube carcinoma 66 farletuzumab 66 hormone refractory prostate cancer 66 recurrent NSCLC 66 pertuzumab 66 relapsed refractory 65 mRCC 65 Doxil ® 65 relapsed refractory multiple myeloma 65 LHRH receptor positive 65 erlotinib Tarceva ® 65 axitinib 65 gastrointestinal stromal tumor GIST 65 recurrent ovarian 65 doublet chemotherapy 65 carboplatin 65 AP# [003] 64 dasatinib Sprycel ® 64 stage chemoresistant ovarian 64 taxane resistant 64 taxane refractory 64 evaluating Xcytrin 64 nab paclitaxel 64 phase IIb clinical 64 metastatic castrate resistant 64 metastatic castration resistant 64 alkylating agent 64 refractory metastatic 64 metastatic melanoma 64 metastatic colorectal cancer 64 NSCLC 64 chronic lymphocytic leukemia CLL 64 sorafenib Nexavar 64 docetaxel 64 metaglidasen 64 dasatinib Sprycel 63 gemcitabine Gemzar 63 advanced metastatic renal 63 solid tumors 63 HGS ETR1 63 metastatic colorectal 63 heavily pretreated patients 63 anti leukemic 63 metastatic CRPC 63 mapatumumab 63 metastatic RCC 63 IV melanoma 63 castrate resistant prostate cancer 63 sorafenib Nexavar ® 63 cisplatin 63 taxane therapy 63 vinca alkaloid 63 Perifosine 63 recurrent glioblastoma multiforme 63 chemotherapy cisplatin 63 chemotherapy regimens 63 panobinostat 63 PI3K/Akt pathway inhibitor 63 pegylated liposomal doxorubicin 63 advanced NSCLC 63 taxane 63 HGS ETR2 63 anthracycline taxane 63 metastatic CRC 63 imatinib Gleevec ® 63 gemcitabine 62 EGFR expressing 62 castration resistant prostate cancer 62 Cloretazine 62 refractory NSCLC 62 Hodgkin lymphoma HL 62 relapsed MM 62 Amrubicin 62 evaluating tivozanib 62 MGd 62 OvaRex ® MAb 62 OncoVEX GM CSF 62 bevacizumab Avastin 62 metastatic colorectal carcinoma 62 gastrointestinal stromal tumors GIST 62 multi kinase inhibitor 62 leukemia CLL 62 antitumor activity 62 cytotoxic chemotherapy 62 chemoradiotherapy 62 IMC A# 62 tumors GIST 62 T DM1 62 systemic anaplastic large 62 neratinib 62 MAGE A3 ASCI 62 trabectedin 62 cisplatin carboplatin 62 tyrosine kinase inhibitors 62 refractory colorectal cancer 62 YONDELIS 62 stage IIIb IV 62 metastatic malignant melanoma 62 imatinib therapy 62 estramustine 62 stage IIIB 62 obatoclax 62 prostate cancer CRPC 62 Panzem R NCD 62 pancreatic adenocarcinoma 62 refractory metastatic colorectal cancer 62 sunitinib malate 62 cell lymphoma CTCL 62 antibody MAb 62 aflibercept VEGF Trap 62 metastatic hormone refractory 62 sunitinib 62 recurrent malignant glioma 62 epithelial ovarian cancer 62 Cloretazine ® 62 elacytarabine 62 radiation sensitizer 62 vinorelbine 62 standard chemotherapy regimen 62 IV metastatic melanoma 61 carboplatin paclitaxel 61 androgen independent 61 docetaxel Taxotere R 61 leukemia AML 61 gemcitabine carboplatin 61 alkylating agents 61 cutaneous T cell 61 refractory CTCL 61 adjuvant therapy 61 Pemetrexed 61 galiximab 61 liposomal doxorubicin 61 refractory cutaneous T 61 tanespimycin 61 cisplatin chemotherapy 61 ELACYT 61 CYT# potent vascular disrupting 61 nonmetastatic 61 CA4P 61 cetuximab Erbitux ® 61 chlorambucil 61 KRN# 61 imetelstat 61 liposomal formulation 61 metastatic renal cell 61 RGB # 61 ixabepilone 61 anticancer agents 61 CML CP 61 histone deacetylase HDAC inhibitor 61 HER2 positive breast cancer 61 metastatic malignant 61 dacarbazine 61 irinotecan doxorubicin oxaliplatin paclitaxel 61 5 FU leucovorin 61 trastuzumab 61 Aplidin 61 bone metastases 61 entinostat 61 sorafenib tablets 61 receptor tyrosine kinase inhibitor 61 FOLFOX6 61 lymphoma CTCL 61 lintuzumab SGN 61 topotecan 61 unresectable 61 indolent NHL 61 hematological malignancies 61 bortezomib Velcade R 61 docetaxel Taxotere ® 61 dacetuzumab 61 iniparib 61 CIMZIA TM certolizumab pegol 61 ganetespib 61 IV malignant melanoma 61 xenograft models 61 proteasome inhibitor 60 cisplatin gemcitabine 60 Phase #b/#a clinical 60 acute promyelocytic leukemia APL 60 imatinib Gleevec 60 chemo radiotherapy 60 refractory AML 60 hepatocellular carcinoma HCC 60 invasive lobular carcinoma 60 IMGN# 60 Cisplatin 60 demonstrated antitumor activity 60 huC# DM4 60 neoadjuvant 60 basal cell carcinoma BCC 60 bendamustine 60 cetuximab Erbitux 60 forodesine 60 metastatic NSCLC 60 BRCA deficient 60 trastuzumab emtansine T DM1 60 IgG1 monoclonal antibody 60 imatinib resistant 60 unresectable locally advanced 60 ovarian carcinoma 60 neoadjuvant treatment 60 temsirolimus 60 trastuzumab DM1 60 palifosfamide 60 Bezielle 60 depsipeptide 60 Ceflatonin 60 protein kinase inhibitor 60 docetaxel Taxotere 60 follicular NHL 60 nilotinib Tasigna ® 60 ponatinib 60 imatinib mesylate 60 Aflibercept 60 etoposide 60 olaparib 60 pain palliation 60 relapsing multiple sclerosis 60 lupus nephritis 60 cilengitide 60 pomalidomide 60 pan HDAC inhibitor 60 cutaneous T 60 glioblastoma multiforme GBM 60 adecatumumab 60 chemotherapeutic agent 60 lenalidomide Revlimid R 60 perifosine 60 Phase Ib clinical trials 60 refractory chronic myeloid 60 CLL SLL 60 EGFR expressing mCRC 60 BR.# 60 aflibercept 60 Herceptin trastuzumab 60 IV NSCLC 60 breast carcinoma 60 cediranib 60 CTAP# Capsules 60 myelofibrosis MF 60 COU AA 60 SCCHN 60 operable breast cancer 60 temozolomide TMZ 60 BRAF inhibitor 60 ongoing Phase 1b 60 Folfox 60 Tyrima 60 bortezomib 60 B CLL 60 systemic ALCL 60 trastuzumab Herceptin ® 60 biliary tract cancer 60 Paraplatin ® carboplatin 60 voreloxin 60 BAY #-# 60 chemotherapy docetaxel 60 Xanafide 60 plus prednisone 60 relapsed CLL 60 irinotecan chemotherapy 60 Phase Ib II 60 metastatic breast cancer 60 Faslodex 60 trastuzumab Herceptin R 60 GRN#L 60 prostate cancer AIPC 60 recurrent GBM 60 irinotecan containing 60 metastatic GIST 60 phase Ib 60 gemcitabine cisplatin 60 prostate cancer mCRPC 60 refractory CLL 60 hematological cancers 60 metastatic squamous cell carcinoma 60 Carfilzomib 60 papillary renal cell carcinoma 60 PXD# 60 VELCADE melphalan 60 glufosfamide 60 CR# vcMMAE 60 chemotherapeutic drug 60 assessing T DM1 59 anti angiogenic therapy 59 Bortezomib 59 Annamycin 59 gemcitabine chemotherapy 59 anti TNF 59 recurrent metastatic 59 SCH # 59 advanced metastatic prostate 59 evaluating T DM1 59 sunitinib Sutent 59 Platinol ® cisplatin 59 VNP#M 59 trastuzumab DM1 T DM1 59 evaluating picoplatin 59 decitabine 59 non resectable 59 fosbretabulin 59 histologies 59 Vicinium TM 59 neoadjuvant therapy 59 Vidaza ® 59 chronic HCV infection 59 viral kinetics 59 enzastaurin 59 Phase Ib clinical 59 Telcyta 59 multiple myeloma MM 59 mTOR inhibitor 59 lorvotuzumab mertansine 59 oblimersen 59 elotuzumab 59 non squamous NSCLC 59 ON #.Na 59 erlotinib 59 Hedgehog Pathway Inhibitor 59 KRAS mutations occur 59 Proxinium TM 59 Panzem NCD 59 evaluating REVLIMID 59 vascular disrupting agent 59 cell lung cancer 59 epithelial ovarian 59 novel histone deacetylase 59 refractory chronic lymphocytic 59 CHOP chemotherapy 59 remission induction 59 relapsed Hodgkin lymphoma 59 acute leukemias 59 orally bioavailable 59 HGS# 59 humanised monoclonal antibody 59 prior chemotherapy regimens 59 ZACTIMA 59 Voreloxin 59 temozolomide 59 chemoradiation 59 monotherapy 59 investigational humanized monoclonal antibody 59 relapsed AML 59 pazopanib 59 non squamous 59 mg/m2 dose 59 localized renal 59 epithelial tumors 59 oral ridaforolimus 59 Omacetaxine 59 fluoropyrimidine 59 previously untreated follicular 59 recurrent prostate cancer 59 Atiprimod 59 tyrosine kinase inhibitor 59 AQ4N 59 rALLy clinical trial 59 Phase 1b clinical 59 Ph + ALL 59 sodium thiosulfate STS 59 eosinophilic asthma 59 AKT inhibitor 59 Tanespimycin 59 metastatic bladder 59 visceral metastases 59 Sanofi Aventis Taxotere 59 CBLC# 59 receiving highly emetogenic 59 pCR 59 talactoferrin 59 eribulin mesylate 59 acute GvHD 59 humanized monoclonal antibody 59 Surgical resection 59 systemic lupus erythematosus SLE 59 Tarceva TM 59 imetelstat GRN#L 59 gastrointestinal stromal tumors 59 seliciclib 59 recurrent glioblastoma 59 cetuximab Erbitux R 59 vandetanib 59 urothelial bladder cancer 59 EOquin TM 59 Cloretazine R VNP#M 59 ThermoDox R 59 paclitaxel Taxol 58 huN# DM1 58 Cloretazine R 58 lintuzumab 58 relapsed GBM 58 advanced carcinoid 58 dose escalation clinical 58 Gleevec resistant 58 vemurafenib 58 essential thrombocythemia ET 58 idarubicin 58 cetuximab 58 taxanes 58 crizotinib PF # 58 Ophena TM 58 gefitinib 58 metastatic SCCHN 58 amrubicin 58 HER2 positive cancers 58 SAR# [004] 58 dacarbazine DTIC 58 Gemzar ® 58 PKC# 58 poly ADP ribose polymerase 58 metastatic kidney 58 refractory indolent non 58 anti EGFR antibody 58 prostate carcinoma 58 gemcitabine Gemzar ® 58 OMP #R# 58 multicenter Phase II 58 Imprime PGG 58 Akt inhibitor 58 VEGFR2 inhibitor 58 cancer mCRC 58 Gleevec imatinib 58 fallopian tube cancers 58 dexamethasone Decadron 58 HER2 + 58 EGFR tyrosine kinase inhibitor 58 ALCL 58 Phase III randomized controlled 58 alpha folate receptor 58 chronic myelogenous leukemia CML 58 anthracyclines 58 5 fluorouracil leucovorin 58 Hsp# Inhibitor 58 immunomodulator 58 Hodgkin lymphoma NHL 58 LUX Lung 58 CANCIDAS 58 cytogenetic responses 58 castrate resistant 58 acute coronary syndromes ACS 58 sunitinib Sutent ® 58 AEG# 58 CYC# 58 virus HCV infection 58 lymphoid malignancies 58 chemotherapeutic regimen 58 Zolinza 58 bladder carcinoma 58 relapsing remitting multiple sclerosis 58 DCVax ® Brain 58 chemopreventive agent 58 cytarabine 58 novel VDA molecule 58 HSP# inhibitor 58 renal cell carcinoma 58 microwave hyperthermia 58 Acute Myeloid Leukemia AML 58 phase IIa clinical 58 nucleoside analog 58 BRIM2 58 randomized Phase III 58 oral deforolimus 58 luteinizing hormone releasing 58 autoantibody positive 58 IMA# 58 R sorafenib tablets 58 seminoma 58 sorafenib Nexavar R 58 chemotherapeutic agents 58 TACE 58 ZOLINZA 58 refractory gout 58 PSMA ADC 58 gefitinib Iressa 58 dasatinib 58 AA Amyloidosis 58 paclitaxel cisplatin 58 EGFR TKI 58 HGS ETR1 mapatumumab 58 esophageal candidiasis 58 clinically localized prostate 58 brain metastases 58 BCIRG 58 ZYBRESTAT fosbretabulin 58 Erlotinib 58 HCV NS5B polymerase 58 Hsp# inhibition 58 haematological cancers 58 invasive candidiasis 58 RCW Breast Cancer 58 relapsed SCLC 58 recurrent squamous cell carcinoma 58 APTIVUS r 58 targeted antifolate 58 locoregional recurrence 58 paclitaxel Taxol R 58 TTF Therapy 58 interferon alfa 2a 58 neoadjuvant chemotherapy 58 nilotinib 58 Taxotere ® 58 MGCD# [001] 58 plus gemcitabine 58 angiogenesis inhibitor 58 Pharmacokinetics PK 58 NEUVENGE 58 HER2 overexpression 58 motesanib 58 Triapine 58 K ras mutations 58 Brentuximab Vedotin SGN 58 Phase 2a clinical 58 paclitaxel chemotherapy 58 Platinol 58 Pralatrexate 58 non metastatic osteosarcoma 58 Traficet EN 58 refractory prostate cancer 58 ToGA 58 deforolimus 58 FUSILEV enhances 58 EGFR inhibitors 58 Golimumab 58 anticancer therapy 58 double blinded randomized 58 antiangiogenic therapy 58 Taxotere chemotherapy 58 epirubicin cyclophosphamide 58 investigational monoclonal antibody 58 GvHD 58 AVASTIN 58 colon carcinoma 58 IMiDs R 58 Ixempra 58 chemotherapeutic 58 orally administered inhibitor 58 targeting CD# 58 postoperative chemotherapy 58 bone metastasis 58 medullary thyroid cancer 58 including eniluracil ADH 58 histologic subtype 58 CTA# Injection 58 relapsing remitting MS RRMS 57 Nexavar sorafenib 57 overlapping toxicities 57 adriamycin 57 mycophenolate mofetil 57 squamous cell histology 57 mertansine 57 EGFR HER2 57 PARP inhibitor 57 picoplatin 57 relapsed leukemia 57 neoplasia 57 prostate cancer CaP 57 malignancies 57 tiuxetan 57 pegylated interferon alpha 57 interferon alfa 57 pancreatic carcinoma 57 hormone refractory 57 PDX pralatrexate 57 Randomized Phase 57 interferon gamma 1b 57 virus HCV protease inhibitor 57 Sipuleucel T 57 inhibitor RG# 57 IMC #B 57 Irinotecan 57 belinostat 57 Pathway Inhibitor 57 hematologic malignancies 57 afatinib 57 FOLOTYN ® 57 Fludarabine 57 anticancer compound 57 concurrent chemoradiation 57 adalimumab Humira 57 locoregional 57 mTOR inhibitors 57 nucleoside analogue 57 OHR/AVR# 57 bevacizumab 57 oral JAK1 57 hormone refractory metastatic prostate 57 dose cohort 57 protease inhibitor PI 57 Epratuzumab 57 stage IIIb 57 advanced unresectable 57 cyclophosphamide methotrexate 57 BCG refractory 57 ErbB2 positive 57 riociguat 57 5 fluorouracil 57 chemotherapeutic regimens 57 anti TNF alpha 57 refractory Hodgkin lymphoma 57 JAK2 inhibitor 57 melphalan prednisone 57 prednisone prednisolone 57 novel anticancer 57 randomized Phase 57 free survival PFS 57 Toxicities 57 Paraplatin ® 57 lumiliximab 57 histone deacetylase inhibitor 57 genotypic resistance 57 malignant pleural mesothelioma 57 M2 subunit 57 LHRH analogues 57 nonsmall cell lung cancer 57 cytotoxic therapy 57 metastatic 57 TLK# 57 randomized discontinuation trial 57 de novo kidney transplant 57 stage IIIB IV 57 Daclizumab 57 refractory acute myeloid 57 Fludara 57 daunorubicin 57 HER2 negative 57 Rituxan rituximab 57 mCRC patients 57 bortezomib Velcade 57 symptomatic BPH 57 diagnosed GBM 57 oral prodrug 57 plus dexamethasone 57 HCV RESPOND 2 57 hematologic cancers 57 azacitidine 57 IRX 2 57 registrational trial 57 ritonavir boosted 57 distant metastasis 57 Diffuse Large B 57 eribulin 57 colorectal liver metastases 57 metastatic disease 57 follicular lymphoma 57 unresectable stage 57 pemetrexed 57 cell lymphoma ALCL 57 diagnosed multiple myeloma 57 mutated KRAS gene 57 albumin bound paclitaxel 57 chronic angina 57 immunotherapeutic agent 57 vinca alkaloids 57 oxaliplatin 57 CCR5 antagonist 57 mCRC 57 unresectable tumors 57 Genasense ® 57 EGFR mutation positive 57 microtubule targeting 57 multicenter randomized placebo controlled 57 Relapsed Refractory 57 kinase inhibition 57 Sudhir Agrawal D.Phil 57 plus prednisone prednisolone 57 HNSCC 57 registrational Phase 57 Cell Lung Cancer 57 CanAg 57 adjuvant chemotherapy 57 dose escalation Phase 57 AEGR 57 systemic RNAi therapeutic 57 debulking surgery 57 INCB# [001] 57 ACTEMRA TM 57 hepatitis C HCV 57 pegylated interferon alfa 2a 57 XL# XL# XL# 57 Blinatumomab 57 Tarceva erlotinib 57 Phase #/#a trial 57 tumor histology 57 selective kinase inhibitor 57 antimetabolite 57 EGFR mutations 57 recurrent metastatic ovarian cancer 57 adjuvant radiation 57 velafermin 57 antiretroviral naïve 57 cytokine refractory 57 chronic myeloid leukemia CML 57 MT# MEDI 57 Gefitinib 57 tyrosine kinase inhibitors TKIs 57 differentiated thyroid 57 systemic lupus erythematosus 57 TASKi3 57 medically inoperable 57 Allovectin 7 57 anthracyclines taxanes 57 Deforolimus 57 Trabectedin 57 abiraterone 57 Azedra 57 pancreatic NET 57 phase IIb trial 57 thalidomide Thalomid 57 talabostat 57 cytostatic 57 IAP inhibitors 57 HuMax EGFr 57 EGFR tyrosine kinase inhibitors 57 Allovectin 7 ® 57 isoform selective 57 2 methoxyestradiol 57 Alpharadin 57 acute myelogenous leukemia AML 57 cutaneous melanoma 57 TKI therapy 57 transcriptase inhibitor NNRTI 57 registrational 56 hematological malignancy 56 oral antiviral 56 standard chemotherapy regimens 56 cabazitaxel 56 mitomycin 56 Tesetaxel 56 IAP inhibitor 56 Cytoxan 56 metastatic gastric 56 ADXS# 56 immunomodulating 56 hepatocellular cancer 56 Picoplatin Efficacy After 56 PD LID 56 cyclophosphamide chemotherapy 56 investigational pan BCR 56 Afatinib 56 myelofibrosis 56 advanced nonsquamous NSCLC 56 cisplatin resistant 56 paclitaxel Taxol ® 56 dose escalation trial 56 compound AEZS 56 prospectively defined 56 VEGF inhibitors 56 DMARD 56 SUCCEED trial 56 kinase inhibitor 56 goserelin 56 ribavirin RBV 56 myelodysplastic syndromes MDS 56 Hormone Refractory Prostate Cancer 56 signal transduction inhibitor 56 TORISEL 56 AVOREN 56 rALLy 56 MKC# MT 56 limiting toxicity 56 zalutumumab 56 tumor recurrence 56 polymerase inhibitor 56 serous ovarian cancer 56 follicular non 56 Sapacitabine 56 unresectable liver cancer 56 capecitabine Xeloda R 56 surgical debulking 56 epirubicin cisplatin 56 regorafenib 56 monoclonal antibody conjugated 56 HCV protease 56 chemotherapy regimen 56 microsphere therapy 56 PREZISTA r 56 Phase 2b clinical 56 HCV protease inhibitor 56 OXi# 56 cytarabine daunorubicin 56 Reolysin 56 pediatric malignancies 56 rituximab Rituxan 56 PNP inhibitor 56 Prostate AdenoCarcinoma Treatment 56 zanolimumab 56 dose dexamethasone 56 EOquin TM phase 56 posaconazole 56 Romidepsin 56 unresectable Stage III 56 adjuvant colon cancer 56 T#I mutation 56 chronic myeloid 56 cell carcinoma RCC 56 non nucleoside HCV 56 capecitabine Xeloda 56 erythropoietic 56 CEQ# 56 antithrombotic 56 Darinaparsin 56 evaluating satraplatin 56 Chemophase 56 BRIM3 56 MyVax R 56 tesetaxel 56 FOLFOX6 chemotherapy regimen 56 relapsed Acute Myeloid 56 tumor subtypes 56 relapsed MCL 56 mitoxantrone plus 56 oral Azacitidine 56 Dasatinib 56 haematological malignancies 56 Hepatocellular Carcinoma HCC 56 AAG geldanamycin analog 56 Enzastaurin 56 antitumor effect 56 MEK inhibitor 56 Exherin TM 56 Gleevec imatinib mesylate 56 hormone receptor positive 56 sodium glucose cotransporter 56 Acute Myelogenous Leukemia AML 56 vismodegib 56 Omnitarg 56 PI3K inhibitor 56 HCV SPRINT 56 hematological diseases 56 HCD# [002] 56 Phase 2a trial 56 Trastuzumab 56 Chronic Lymphocytic Leukemia CLL 56 leukemia ALL 56 dose cytarabine 56 Nexavar ® 56 Phase IIIb clinical 56 TASKi2 56 tolerability pharmacokinetics 56 Cutaneous T 56 Telintra 56 Albuferon TM 56 Phase Ib study 56 Pegylated Interferon 56 custirsen 56 XL# XL# XL# XL# 56 Satraplatin 56 Aurora kinase 56 Curaxin CBLC# 56 lymphocytosis 56 TREANDA 56 Virulizin ® 56 CIMZIA ™ 56 satraplatin Phase 56 Glufosfamide 56 resectable 56 mucinous 56 tesmilifene 56 CLL8 56 imatinib 56 panitumumab Vectibix 56 Temsirolimus 56 biologic therapy 56 visilizumab 56 phase IIb study 56 Neuvenge 56 rituximab 56 HER2 positive 56 Hsp# inhibitor 56 BEACOPP 56 DermaVir Patch 56 dacarbazine chemotherapy 56 JAK inhibitor 56 chemos 56 vincristine doxorubicin 56 EndoTAGTM 1 56 interferon beta therapy 56 non nucleoside inhibitor 56 grade cervical intraepithelial 56 Solazed TM 56 indolent follicular non 56 anti mitotic 56 ASA# 56 microtubule inhibitor 56 DAVANAT 56 phase IIb 56 HuMax CD4 56 lymphomas leukemias 56 cell malignancies 56 metastatic renal 56 thymalfasin 56 metastatic cancer 56 pegylated interferons 56 metastatic sarcoma 56 fluorouracil 56 endocrine therapies 56 interferon alfa 2b 56 molecularly targeted 56 DAPT 56 iniparib BSI 56 allogeneic HSCT 56 EGFR TKIs 56 cytogenetic response 56 evaluable 56 ProLindac 56 Myelofibrosis 56 Quinamed 56 PEGylated interferon beta 1a 56 Ceflatonin R 56 SNT MC# 56 Pegasys ® 56 Pertuzumab 56 Taxotere R 56 dependent kinase inhibitor 56 targeted radiotherapeutic 56 tyrosine kinase inhibitor TKI 56 Alemtuzumab 56 metastatic HER2 negative 56 antibody MT# 56 peritoneal cancer 56 pegfilgrastim 56 low dose cytarabine 56 advanced hepatocellular carcinoma 56 acetonide FA 56 investigational compound 56 OMP #M# 56 unique alkylating agent 56 romidepsin 56 adjuvant cisplatin 56 leukemia CML 55 TRO# 55 pralatrexate 55 carfilzomib 55 apoptosis inducer 55 fulvestrant 55 Xeloda ® 55 doxorubicin 55 modified glutathione analog 55 elesclomol 55 autologous transplants 55 FOLOTYN 55 placebo controlled clinical 55 ENMD 55 colorectal cancer liver metastases 55 advanced HER2 positive 55 naïve HCV 55 xanthine oxidase inhibitor 55 adjuvant radiotherapy 55 INSPIRE Trial Phase III 55 DCVax R Brain 55 figitumumab 55 oral clodronate 55 IL# PE#QQR 55 liver metastases 55 Aplidin R 55 disease modifying antirheumatic 55 ibritumomab tiuxetan 55 glucocorticoid induced osteoporosis 55 myelosuppression 55 ara C 55 rituximab refractory 55 capecitabine 55 familial amyloidotic polyneuropathy FAP 55 erlotinib Tarceva 55 metastatic pancreatic 55 follicular lymphoma FL 55 oral anticancer 55 invasive bladder 55 Bevacizumab 55 dose cohorts 55 Seliciclib 55 Advaxis Phase 55 decompensated liver disease 55 BrachySil TM 55 cyclophosphamide 55 Revlimid lenalidomide 55 virologic response 55 cisplatin vinorelbine 55 evaluating ispinesib